445 related articles for article (PubMed ID: 21442469)
1. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
3. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
4. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
6. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
8. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).
Farah NB; Ghanem R; Amr M
BMC Urol; 2014 Jan; 14():11. PubMed ID: 24468269
[TBL] [Abstract][Full Text] [Related]
9. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
Contieri R; Tan WS; Grajales V; Hensley PJ; Martini A; Bree K; Myers A; Nogueras-Gonzalez G; Navai N; Dinney CP; Guo C; Kamat AM
BJU Int; 2024 Jun; 133(6):733-741. PubMed ID: 38374533
[TBL] [Abstract][Full Text] [Related]
10. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
[TBL] [Abstract][Full Text] [Related]
11. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
12. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
13. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
14. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
15. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
[TBL] [Abstract][Full Text] [Related]
16. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
17. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
[TBL] [Abstract][Full Text] [Related]
18. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
[TBL] [Abstract][Full Text] [Related]
19. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
20. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years.
Patard J; Moudouni S; Saint F; Rioux-Leclercq N; Manunta A; Guy L; Ballanger P; Lanson Y; Hajri M; Irani J; Guillé F; Beurton D; Lobel B;
Urology; 2001 Oct; 58(4):551-6. PubMed ID: 11597537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
